ANI 制药
ANIP
72.29
+0.01
+0.01%
ANI 制药
US · ANIP
#2919 按市值排名
上市于 1970
72.29
+0.01
+0.01%
实时 - 追踪5344个代码 - 心跳于320秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 117.58% +0.03pp
- 机构数量
- 365 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund80.29%
Hedge Fund17.17%
Public Company8.55%
Individual/Insider6.18%
VC/PE Fund4.73%
Private Company3.85%
Government Pension Fund2.83%
主要股东 截至 2026-06-30
BlackRock
13.81% · 2.96M 股
MVP Capital Partners
4.73% · 1.01M 股
Vanguard Capital Management, LLC
4.53% · 971.81K 股
Soleus Capital Management, L.P.
4.05% · 867.76K 股
State Street Global Advisors
3.88% · 831.65K 股
Tang Capital Management, LLC
3.30% · 707.50K 股
Dimensional Fund Advisors
2.91% · 623.46K 股
American Century Investment Management
2.68% · 574.47K 股
Arrowstreet Capital, Limited Partnership
2.62% · 562.02K 股
Global Alpha Capital Management Ltd.
2.60% · 558.00K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 6次买入 · 44次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Nikhil Lalwani | Chief Executive Officer | 1.58% |
| Chad Gassert | Senior Vice President of Corporate Development & Strategy | 1.09% |
| Stephen Carey | Chief Financial Officer | 0.79% |
| Muthusamy Shanmugam | Head of R&D, COO of Novitium Operations & Director | 0.39% |
| Ori Gutwerg | Senior Vice President of Generics | 0.35% |
| Meredith Cook | Senior Vice President | 0.34% |
| Christopher Mutz | Head of Rare Disease | 0.29% |
| Krista Davis | Chief Human Resources Officer | 0.24% |
| Thomas Haughey | Independent Director | 0.18% |
| Patrick Walsh | Chairperson | 0.18% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $73.00 |
| 2026-09-14 | Nikhil Lalwani | Chief Executive Officer | Automatic Disposition | -5,400 | $71.00 |
| 2026-09-13 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $70.79 |
| 2026-09-10 | Jeanne Thoma | Independent Director | Automatic Disposition | -1,000 | $71.53 |
| 2026-08-30 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $72.80 |
| 2026-08-24 | Nikhil Lalwani | Chief Executive Officer | Automatic Disposition | -5,400 | $74.30 |
| 2026-08-18 | Henry Gosebruch | Director | Other Acquisition | +6,662 | -- |
| 2026-08-12 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $75.48 |
| 2026-08-09 | Ori Gutwerg | Senior Vice President of Generics | Open Market Disposition | -3,162 | $77.00 |
| 2026-07-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $81.36 |
| 2026-07-17 | Meredith Cook | Senior Vice President | Sale to Issuer | -2,466 | $79.20 |
| 2026-07-12 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $81.84 |
| 2026-07-06 | Patrick Walsh | Chairperson | Intent to Sell (Form 144) | -4,336 | $86.19 |
| 2026-07-01 | Stephen Carey | Chief Financial Officer | Derivative Exercise and Sale | -3,313 | $49.51–86.00 |
| 2026-06-28 | Stephen Carey | Chief Financial Officer | Automatic Disposition | -2,850 | $84.12 |
| 2026-06-11 | Meredith Cook | Senior Vice President | Automatic Disposition | -500 | $82.03 |
| 2026-06-07 | Thomas Haughey | Independent Director | Automatic Disposition | -2,000 | $80.88 |
| 2026-06-04 | Stephen Carey | Chief Financial Officer | Derivative Exercise and Sale | -3,312 | $49.51–80.00 |
| 2026-05-20 | Antonio Pera | Independent Director | Other Acquisition | +4,357 | -- |
| 2026-05-20 | Thomas Haughey | Independent Director | Other Acquisition | +4,357 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
ANI 制药 讨论区 0 条评论